Study Status
Concluded
DAIDS Number
10787
IND Number
108,894
Clinical Trials Link
Primary Protocol Team Members
Summary
P1083 was a phase II/III, intensive pharmacokinetic study of Lopinavir/Ritonavir (LPV/r) in HIV-infected infants and children ≥3 to <25 kg (stratified by weight) initiating LPV/r therapy at U.S. and non-U.S. IMPAACT sites. The objectives of this study were to determine if the weight band antiretroviral (ARV) dosing recommendations of the WHO provide safe and tolerable dosing of LPV/r when administered as the heat stable pediatric tablet or the liquid formulation as part of a combination ARV regimen and to delineate the pharmacokinetics of LPV/r when dosed according to the WHO ARV weight band dosing schedule in HIV-infected infants and children.